None
Conditions
Interventions
intervention group:Administration of Oliceridine + The initial concentration of remifentanil is 3.0ng/ml, with an increasing/decreasing concentration gradient of 0.3ng/ml
control group:Equal volume physiological saline + The initial concentration of remifentanil is 3.0ng/ml, with an increasing/decreasing concentration gradient of 0.3ng/ml
Sponsors
Chongqing University Fuling Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) 18 = age = 70 years, ASA class I-II, 18 kg/m2 = BMI = 28 kg/m2, regardless of gender; (2) Minimally invasive surgery under general anesthesia with tracheal intubation and mechanical ventilation; (3) Estimated operating time <2 hours; (4) Those who voluntarily signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Known allergy to the study drug or belonging to a susceptible population; (2) Presence of contraindications to general anesthesia; (3) Presence of severe cardiac or cerebrovascular disease, respiratory disease, hematologic disease, endocrine disease, or hepatic or renal dysfunction; (4) Predictable difficult airway (Mallampati class III or IV) or the presence of laryngoscopic exposure difficulties and intubation difficulties of high-risk factors: cervical spine disease, dental anomalies, small jaws, openness <3 fingers, history of sleep apnea syndrome and snoring, upper respiratory tract disease symptoms, subglottic stenosis, enlarged thyroid or tonsils, mediastinal masses, pharyngeal tumors, etc.; (5) The presence of general anesthesia contraindications; (6) The presence of severe cardiovascular and cerebrovascular diseases, blood diseases, endocrine diseases or liver and kidney disorders. (5) Surgery or use of experimental drugs within one week prior to surgery; (6) Communication disorders, including dyslexia, dyspraxia, visual impairment, or auditory impairment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Half effective concentration (EC50) and 95% confidence interval (CI) of remifentanil that provides satisfactory intubation conditions and no significant tracheal intubation response during general anesthesia tracheal intubation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain score;Adverse reaction incidence rate;Mean invasive arterial blood pressure, mean heart rate; | — |
Countries
China
Contacts
Public ContactKeyu He
Chongqing University Fuling Hospital
Outcome results
None listed